Birsfelden, Switzerland

Robert George Ridley

This inventor holds 1 USPTO granted patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 2000.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Robert George Ridley

Introduction

Robert George Ridley is a notable inventor based in Birsfelden, Switzerland. He has made significant contributions to the field of medicinal chemistry, particularly in the fight against malaria. His work focuses on developing compounds that can effectively treat or prevent this life-threatening disease.

Latest Patents

One of Ridley's key patents is for .beta.-Alkoxyacrylates against malaria. This invention relates to compounds that are particularly useful in treating both chloroquine-sensitive and chloroquine-resistant malaria. The compounds are defined by specific formulae, which include various substituents that enhance their efficacy in combating the disease.

Career Highlights

Ridley is associated with Hoffmann-La Roche Inc., a leading global healthcare company. His work at the company has allowed him to contribute to important advancements in pharmaceutical research and development. His innovative approach has positioned him as a valuable asset in the ongoing battle against malaria.

Collaborations

Throughout his career, Ridley has collaborated with esteemed colleagues such as Christian N Hubschwerlen and Hugues Matile. These collaborations have fostered a productive environment for research and innovation, leading to significant advancements in the field.

Conclusion

Robert George Ridley's contributions to the field of medicinal chemistry, particularly in malaria treatment, highlight the importance of innovation in healthcare. His work continues to inspire future research and development in the fight against infectious diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…